Healthcare Innovation Delivered to Your Inbox Every Week
Healthcare leaders already subscribed
Unsubscribe anytime. We respect your privacy.
"The best healthcare newsletter I've read. Dr. John's insights are always practical, data-driven, and immediately actionable."
— Pharmacy Owner, California
Explore Dr. John's latest LinkedIn articles on AI innovation, pharmacy practice, and healthcare transformation. Fresh insights delivered weekly.
7 articles found
If you're not in the weeds of tech, MCP (Model Context Protocol) probably sounds like jargon. Let me break it down simply. Think of healthcare like a hospital system: You've got the ER, pharmacy, lab, billing, and outpatient clinics. Each has its own workflows, its own staff, and its own language.
The FDA recently issued a statement about GLP-1 medications and compounding. While much of the focus has been on "unapproved drugs," one aspect that deserves more attention is the green list of approved manufacturers and suppliers. This is a meaningful step forward.
I've always been fascinated by speed—on the racetrack and in the world of startups. In my early days of motorcycle racing, I learned a crucial lesson that applies just as much to business strategy as it does to navigating tight corners at high speeds.
Before we dive into Texas, let's take a quick look at Arkansas — where one of the most significant pharmacy reforms in recent history began. Texas Senate Bill 1236 represents a major step forward for community pharmacy practice and patient access to care.
If you're not in the weeds of tech, MCP (Model Context Protocol) probably sounds like jargon. Let me break it down simply. Think of healthcare like a hospital system: You've got the ER, pharmacy, lab, billing, and outpatient clinics. Each has its own workflows, its own staff, and its own language.
The FDA recently issued a statement about GLP-1 medications and compounding. While much of the focus has been on "unapproved drugs," one aspect that deserves more attention is the green list of approved manufacturers and suppliers. This is a meaningful step forward.
Hey everyone—remember when President Trump signed that "Delivering Most-Favored-Nation Prescription Drug Pricing to..." Exploring who truly benefits from the GLP-1 medication revolution and the accessibility challenges that remain.
In an era where a ten-second TikTok can reach millions, the traditional pillars of medical advice—peer-reviewed research and clinical expertise—are being overshadowed by social media influencers. This trend is creating dangerous consequences for patient care.
As a pharmacist and a self-professed mechanism-of-action enthusiast, I've closely tracked the evolution of treatments for diabetes and obesity. The latest addition to the GLP-1 family, Orforglipron, represents an exciting development in oral medication delivery.
I've always been fascinated by speed—on the racetrack and in the world of startups. In my early days of motorcycle racing, I learned a crucial lesson that applies just as much to business strategy as it does to navigating tight corners at high speeds.
Before we dive into Texas, let's take a quick look at Arkansas — where one of the most significant pharmacy reforms in recent history began. Texas Senate Bill 1236 represents a major step forward for community pharmacy practice and patient access to care.